AR125902A1 - Compuestos y métodos dirigidos a epirregulina - Google Patents
Compuestos y métodos dirigidos a epirregulinaInfo
- Publication number
- AR125902A1 AR125902A1 ARP220101316A ARP220101316A AR125902A1 AR 125902 A1 AR125902 A1 AR 125902A1 AR P220101316 A ARP220101316 A AR P220101316A AR P220101316 A ARP220101316 A AR P220101316A AR 125902 A1 AR125902 A1 AR 125902A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- comprises seq
- pain
- chronic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title 1
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102000043415 human EREG Human genes 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 102000007134 Epiregulin Human genes 0.000 abstract 2
- 101800000155 Epiregulin Proteins 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 2
- 239000010839 body fluid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000008035 Back Pain Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000008930 Low Back Pain Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
Abstract
La presente invención se refiere a anticuerpos de epirregulina, composiciones que los comprenden, y métodos para fabricar y/o usar los anticuerpos y/o sus composiciones para trastornos del dolor crónico tales como dolor de osteoartritis crónico, o dolor de neuropatía periférica diabética crónico, o dolor lumbar crónico. Reivindicación 1: Un anticuerpo que se une a epirregulina humana, en donde el anticuerpo comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), en donde la VH comprende regiones determinantes de complementariedad de la cadena pesada (HCDR) HCDR1, HCDR2 y HCDR3, y la VL comprende regiones determinantes de complementariedad de la cadena ligera (LCDR) LCDR1, LCDR2 y LCDR3, en donde la HCDR1 comprende la SEQ ID Nº 5, la HCDR2 comprende la SEQ ID Nº 6, la HCDR3 comprende la SEQ ID Nº 7, la LCDR1 comprende la SEQ ID Nº 8, la LCDR2 comprende la SEQ ID Nº 9 y la LCDR3 comprende la SEQ ID Nº 10. Reivindicación 2: El anticuerpo de la reivindicación 1, en donde la VH comprende la SEQ ID Nº 3 y la VL comprende la SEQ ID Nº 4. Reivindicación 3: El anticuerpo de la reivindicación 1 o 2, en donde el anticuerpo comprende una cadena pesada (HC) que comprende la SEQ ID Nº 1 y una cadena ligera (LC) que comprende la SEQ ID Nº 2. Reivindicación 4: Un ácido nucleico que comprende la secuencia de la SEQ ID Nº 11 o 12. Reivindicación 14: Un método para tratar un trastorno del dolor en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad con eficacia terapéutica del anticuerpo de una cualquiera de las reivindicaciones 1 - 3 o 12, o la composición farmacéutica de la reivindicación 13. Reivindicación 28: Un método para determinar el nivel de epirregulina humana en una muestra de fluido corporal que comprende: (a) poner en contacto la muestra de fluido corporal con un anticuerpo monoclonal de diagnóstico anti-epirregulina humana, o un fragmento de unión a antígeno de este, de una cualquiera de las reivindicaciones 1 - 3; (b) opcionalmente, eliminar cualquier anticuerpo monoclonal unido no específicamente o fragmento de unión a antígeno de este; y (c) detectar y/o cuantificar la cantidad de anticuerpo monoclonal, o fragmento de unión a antígeno de este, que se une específicamente a epirregulina humana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191496P | 2021-05-21 | 2021-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125902A1 true AR125902A1 (es) | 2023-08-23 |
Family
ID=82100776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101316A AR125902A1 (es) | 2021-05-21 | 2022-05-17 | Compuestos y métodos dirigidos a epirregulina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220372124A1 (es) |
| EP (1) | EP4341288A1 (es) |
| KR (1) | KR20240009488A (es) |
| CN (1) | CN117440968A (es) |
| AR (1) | AR125902A1 (es) |
| AU (1) | AU2022277694A1 (es) |
| BR (1) | BR112023021829A2 (es) |
| CA (1) | CA3218753A1 (es) |
| CO (1) | CO2023015694A2 (es) |
| CR (1) | CR20230538A (es) |
| DO (1) | DOP2023000253A (es) |
| EC (1) | ECSP23087684A (es) |
| IL (1) | IL308533A (es) |
| PE (1) | PE20240416A1 (es) |
| TW (1) | TW202313680A (es) |
| WO (1) | WO2022246078A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4969440B2 (ja) * | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| AR085484A1 (es) | 2011-04-06 | 2013-10-02 | Lilly Co Eli | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |
| EP2935333A1 (en) * | 2012-12-21 | 2015-10-28 | Sykehuset Sorlandet HF | Egfr targeted therapy of neurological disorders and pain |
-
2022
- 2022-05-17 AR ARP220101316A patent/AR125902A1/es unknown
- 2022-05-17 TW TW111118361A patent/TW202313680A/zh unknown
- 2022-05-19 WO PCT/US2022/030058 patent/WO2022246078A1/en active Application Filing
- 2022-05-19 BR BR112023021829A patent/BR112023021829A2/pt unknown
- 2022-05-19 AU AU2022277694A patent/AU2022277694A1/en active Pending
- 2022-05-19 KR KR1020237043633A patent/KR20240009488A/ko unknown
- 2022-05-19 CN CN202280036392.XA patent/CN117440968A/zh active Pending
- 2022-05-19 US US17/748,405 patent/US20220372124A1/en active Pending
- 2022-05-19 EP EP22731371.5A patent/EP4341288A1/en active Pending
- 2022-05-19 PE PE2023003081A patent/PE20240416A1/es unknown
- 2022-05-19 CA CA3218753A patent/CA3218753A1/en active Pending
- 2022-05-19 CR CR20230538A patent/CR20230538A/es unknown
- 2022-05-19 IL IL308533A patent/IL308533A/en unknown
-
2023
- 2023-11-16 DO DO2023000253A patent/DOP2023000253A/es unknown
- 2023-11-20 CO CONC2023/0015694A patent/CO2023015694A2/es unknown
- 2023-11-21 EC ECSENADI202387684A patent/ECSP23087684A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3218753A1 (en) | 2022-11-24 |
| DOP2023000253A (es) | 2023-12-29 |
| TW202313680A (zh) | 2023-04-01 |
| AU2022277694A9 (en) | 2023-12-07 |
| US20220372124A1 (en) | 2022-11-24 |
| ECSP23087684A (es) | 2023-12-29 |
| CN117440968A (zh) | 2024-01-23 |
| CO2023015694A2 (es) | 2023-11-30 |
| AU2022277694A1 (en) | 2023-11-30 |
| WO2022246078A1 (en) | 2022-11-24 |
| BR112023021829A2 (pt) | 2023-12-19 |
| EP4341288A1 (en) | 2024-03-27 |
| CR20230538A (es) | 2023-12-11 |
| IL308533A (en) | 2024-01-01 |
| PE20240416A1 (es) | 2024-03-05 |
| KR20240009488A (ko) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| RU2012138703A (ru) | Терапевтические и диагностические способы с применением анти-cd200 антител | |
| DK2493503T3 (en) | DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| CN111454359B (zh) | Cd47抗体或其免疫活性片段及应用 | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| CO6180431A2 (es) | Anticuerpos e inmunoconjugados y sus usos | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| EA202092491A1 (ru) | Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение | |
| RU2019104980A (ru) | Анти-icos антитела | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| RU2018129180A (ru) | Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| JP7431750B2 (ja) | カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用 | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| PE20231030A1 (es) | Compuestos y metodos dirigidos a interleucina-34 | |
| HRP20120975T1 (hr) | Terapeutska upotreba anti-cs1 antitijela | |
| AR125902A1 (es) | Compuestos y métodos dirigidos a epirregulina | |
| RU2020128081A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| RU2016127196A (ru) | Способ лечения ран | |
| KR20190130506A (ko) | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |